Combination antiretroviral therapy (cART) has transformed the lives of people living with HIV. Studies suggest that treatment with cART might lead to the normal to near-normal life expectancy. Over the past decade our understanding of the toxic effects of cART has improved and new, convenient, seemingly less toxic, and more tolerable antiretroviral drugs in old and new classes have become available. Once or twice daily regimens—in particular fixed-dose once-daily combinations of two or three drugs—have simplified cART and made lifelong prescription far more acceptable.
Go to Source
Related posts:
- [Comment] Dolutegravir—a promising antiretroviral in development
- [Articles] Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial
- Impact of Drug Stock-Outs on Death and Retention to Care among HIV-Infected Patients on Combination Antiretroviral Therapy in Abidjan, Côte d’Ivoire.
- Effectiveness of Early Antiretroviral Therapy Initiation to Improve Survival among HIV-Infected Adults with Tuberculosis: A Retrospective Cohort Study
- Improved antiretroviral treatment outcome in a rural African setting is associated with cART initiation at higher CD4 cell counts and better general health condition
